178 related articles for article (PubMed ID: 36877344)
1. The effects of Abemaciclib on cell cycle and apoptosis regulation in anaplastic thyroid cancer cells.
Abutorabi ES; Poursheikhani A; Kashani B; Shamsaiegahkani S; Haghpanah V; Bashash D; Mousavi SA; Momeny M; Ghaffari SH
Mol Biol Rep; 2023 May; 50(5):4073-4082. PubMed ID: 36877344
[TBL] [Abstract][Full Text] [Related]
2. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma.
Samimi H; Haghpanah V; Irani S; Arefian E; Sohi AN; Fallah P; Soleimani M
Daru; 2019 Jun; 27(1):1-7. PubMed ID: 31077090
[TBL] [Abstract][Full Text] [Related]
3. Abemaciclib (CDK4/6 Inhibitor) Blockade Induces Cytotoxicity in Human Anaplastic Thyroid Carcinoma Cells.
Seyed Abutorabi E; Irani S; Yaghmaie M; Ghaffari SH
Rep Biochem Mol Biol; 2020 Jan; 8(4):438-445. PubMed ID: 32582803
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM
J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the anticancer effect of telomerase inhibitor BIBR1532 in anaplastic thyroid cancer in terms of apoptosis, migration and cell cycle.
Turkmen E; Sogutlu F; Erdogan M; Biray Avci C
Med Oncol; 2023 Jun; 40(7):196. PubMed ID: 37284891
[TBL] [Abstract][Full Text] [Related]
6. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
[TBL] [Abstract][Full Text] [Related]
7. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
8. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
[TBL] [Abstract][Full Text] [Related]
9. Alantolactone induces concurrent apoptosis and GSDME-dependent pyroptosis of anaplastic thyroid cancer through ROS mitochondria-dependent caspase pathway.
Hu Y; Wen Q; Cai Y; Liu Y; Ma W; Li Q; Song F; Guo Y; Zhu L; Ge J; Zeng Q; Wang J; Yin C; Zheng G; Ge M
Phytomedicine; 2023 Jan; 108():154528. PubMed ID: 36343549
[TBL] [Abstract][Full Text] [Related]
10. Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells.
Allegri L; Baldan F; Mio C; Puppin C; Russo D; Kryštof V; Damante G
Oncol Rep; 2016 Apr; 35(4):2413-8. PubMed ID: 26884249
[TBL] [Abstract][Full Text] [Related]
11. Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer.
Haghpanah V; Fallah P; Tavakoli R; Naderi M; Samimi H; Soleimani M; Larijani B
Tumour Biol; 2016 Jan; 37(1):1299-308. PubMed ID: 26289851
[TBL] [Abstract][Full Text] [Related]
12. Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma.
Geng M; Yang Y; Cao X; Dang L; Zhang T; Zhang L
Biochem Biophys Res Commun; 2019 Dec; 520(3):544-550. PubMed ID: 31615655
[TBL] [Abstract][Full Text] [Related]
13. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
[TBL] [Abstract][Full Text] [Related]
14. Blocking CDK7-Mediated NOTCH1-cMYC Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
Doolittle WKL; Zhao L; Cheng SY
Thyroid; 2022 Aug; 32(8):937-948. PubMed ID: 35822558
[No Abstract] [Full Text] [Related]
15. PLK4 inhibitor exhibits antitumor effect and synergizes sorafenib via arresting cell cycle and inactivating Wnt/β-catenin pathway in anaplastic thyroid cancer.
Zhu W; Xie B
Cancer Biol Ther; 2023 Dec; 24(1):2223383. PubMed ID: 37351847
[TBL] [Abstract][Full Text] [Related]
16. Small interfering RNA (siRNA) against Slug induces apoptosis and sensitizes human anaplastic thyroid carcinoma cells to doxorubicin.
Pan Y; Liu P; Chen D; Dou L
Cancer Biomark; 2017; 18(4):357-366. PubMed ID: 28128736
[TBL] [Abstract][Full Text] [Related]
17. Effects of nutraceuticals on anaplastic thyroid cancer cells.
Allegri L; Rosignolo F; Mio C; Filetti S; Baldan F; Damante G
J Cancer Res Clin Oncol; 2018 Feb; 144(2):285-294. PubMed ID: 29197967
[TBL] [Abstract][Full Text] [Related]
18. Down-Regulation of the Mammalian Target of Rapamycin (mTOR) Pathway Mediates the Effects of the Paeonol-Platinum(II) Complex in Human Thyroid Carcinoma Cells and Mouse SW1736 Tumor Xenografts.
He L; Guo S; Zhu T; Chen C; Xu K
Med Sci Monit; 2020 Jun; 26():e922561. PubMed ID: 32594094
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.
Wunderlich A; Fischer M; Schlosshauer T; Ramaswamy A; Greene BH; Brendel C; Doll D; Bartsch D; Hoffmann S
Cancer Sci; 2011 Apr; 102(4):762-8. PubMed ID: 21214672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]